Scilex Holding Company: Pioneering Non-Opioid Pain Management Solutions and Ensuring Affordable Access Across the U.S.
PALO ALTO, Calif. June 10, 2024
Scilex Holding Company (Nasdaq: SCLX), an innovative revenue-generating firm specializing in non-opioid pain management, has made remarkable strides in expanding the accessibility of its product portfolio. The company’s unwavering commitment to the development, acquisition, and commercialization of sophisticated pain management solutions for acute and chronic pain conditions continues to shape new paradigms in the field.
In a recent announcement, Scilex disclosed that stocking of GLOPERBA® is actively underway in all U.S. wholesalers with which the company has stocking arrangements. GLOPERBA®, a prophylactic treatment for painful gout flares in adults, is FDA-approved and officially launched today. This advancement underscores Scilex’s dedication to offering non-opioid alternatives to conventional pain treatments.
Moreover, Scilex’s strategic initiatives to enhance affordability have consistently set new standards. On April 9, 2024, the company declared the rollout of co-pay programs tailored for its ZTlido® and ELYXYB® products, targeted at commercially insured patients. This initiative caps out-of-pocket costs at a maximum of $25 per month, with certain eligible patients benefiting from paying as little as $0. This affordability measure applies to ZTlido®, a postherpetic neuralgia pain product, and ELYXYB®, a treatment for migraines.
Earlier, on March 21, 2024, Scilex announced another significant measure to lower out-of-pocket expenses across its product line for commercially insured patients. Apart from ZTlido® and ELYXYB®, this cost reduction policy includes GLOPERBA®, further reinforcing the company’s pledge to make non-opioid pain management solutions more accessible. This initiative also anticipates the proactive measures for GLOPERBA®’s launch, ensuring patients benefit from reduced financial burdens right from the product’s introduction.
Scilex’s strategic investments are emblematic of the company’s relentless pursuit to mitigate the affordability barriers that patients often face. By adopting these measures, Scilex is continuing to build on its commitment to provide broad patient access to non-opioid pain management products, thereby positioning itself as a leader in revolutionizing pain treatment across the country.
These steps forward mark a pivotal period for Scilex Holding Company as it not only innovates in pain management but also sets benchmarks in patient affordability and accessibility. The successful delivery of these products through various wholesalers and the strategic enhancement of financial assistance programs underline Scilex’s comprehensive approach to patient careaddressing both the medical and economic aspects of treatment.
With the U.S. healthcare landscape continuously evolving, Scilex’s initiatives are a testament to their forward-thinking and patient-centric strategies, designed to meet the growing needs of those suffering from pain while minimizing dependence on opioid-based treatments.
As Scilex continues to expand and enhance its portfolio, the company’s sustained investments in patient affordability, accessibility, and innovation are setting new standards. These efforts not only resonate with their corporate ethos but also significantly impact the lives of countless patients seeking effective and economically viable pain management options.
Scilex: Advancing Non-Opioid Pain Management and Cost Accessibility for U.S. Patients
Comments